GlaxoSmithKline reported Tuesday at the American Association for the Study of Liver Diseases annual meeting that in two late-stage trials, its experimental drug eltrombopag helped patients with thrombocytopenia achieve "statistically significant" improvement in sustained virological response (SVR).
"The ENABLE trials provide insight into a population that has generally been excluded from clinical trials because they are unable to initiate interferon therapy," remarked Rafael Amado, senior vice president of Oncology Development at GlaxoSmithKline.
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
Subscribe to:
Post Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud
No comments:
Post a Comment